(CNMD) CONMED - Ratings and Ratios

CONMED Corporation (NYSE:CNMD) is a medical technology company that designs, manufactures, and distributes surgical devices and equipment globally. The companys product portfolio is divided into several key categories, each addressing specific surgical needs. In orthopedic surgery, CONMED offers a range of products such as BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors. These products provide solutions for soft tissue repair and are complemented by tools that facilitate minimally invasive sports medicine surgeries. The company markets these orthopedic products under the Hall, CONMED Linvatec, Concept, and Shutt brands.

In addition to orthopedic solutions, CONMED provides general surgery products, including clinical insufflation systems under the AirSeal brand and smoke removal devices under the Buffalo Filter brand. Their endomechanical products include tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, all of which are essential for minimally invasive surgeries. The company also offers electrosurgical solutions, comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and accessories.

CONMEDs endoscopic technologies encompass both therapeutic and diagnostic products used in gastroenterology procedures. These products address various conditions, including dilatation, hemostasis, biliary issues, structure management, and infection prevention. Furthermore, the company provides patient monitoring solutions, such as ECG and EEG electrodes and cardiac defibrillation pads. CONMEDs distribution channels include direct sales to healthcare institutions and partnerships with medical specialty distributors. Founded in 1970, the company is headquartered in Largo, Florida.

Based on the provided data, here is a 3-month forecast:

Over the next three months, CONMED Corporations stock price is expected to range between $54.33 and $60.05, considering the last price of $57.19, an ATR of 2.86, and the SMA20 at $51.69. The stock may face resistance around the SMA50 level of $56.67 and potentially break out above $60.05 if momentum increases.

With a market cap of $1.568B, a P/E of 11.93, and a forward P/E of 27.03, CONMEDs valuation suggests that the market anticipates significant earnings growth. The RoE of 13.76% indicates efficient profitability. However, the P/S ratio of 1.20 reflects moderate revenue valuation. Investors should monitor upcoming earnings reports and industry trends for further guidance.